The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs
- 1 February 2005
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 32 (2), 157-164
- https://doi.org/10.1016/j.nucmedbio.2004.11.003
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Pharmacokinetics and biodistribution of genetically engineered antibodiesCurrent Opinion in Biotechnology, 2002
- Design and application of diabodies, triabodies and tetrabodies for cancer targetingJournal of Immunological Methods, 2001
- Divalent Forms of CC49 Single-Chain Antibody Constructs in Pic) pastoris: Expression, Purification, and CharacterizationThe Journal of Biochemistry, 2000
- Generating improved single-chain Fv molecules for tumor targetingJournal of Immunological Methods, 1999
- Single‐Chain Antibodies in Pancreatic CancerAnnals of the New York Academy of Sciences, 1999
- Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN-14 F(ab)2Cancer, 1996
- Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancerEuropean Journal Of Cancer, 1995
- Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) AntibodyNew England Journal of Medicine, 1993
- Renal filtration, transport, and metabolism of low-molecular-weight proteins: A reviewKidney International, 1979
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970